此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

2020年3月18日 更新者:Millennium Pharmaceuticals, Inc.

A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects With Advanced Malignancies Followed by an Expansion in Subjects With Measurable Disease

This is a Phase I, open label, Dose Escalation study of oral administration of single agent MLN0128 in participants with Advanced Malignancies followed by an Expansion Phase in participants with renal cell carcinoma, endometrial cancer or urothelial cancer who have measurable disease.

研究概览

地位

完全的

干预/治疗

详细说明

The drug being tested in this study is called MLN0128. MLN0128 is being tested to treat people who have Advanced Malignancies.

The study enrolled approximately 198 patients. Participants were assigned to one of the following dose regimens in the Dose Escalation Phase to establish the Maximum Tolerated Dose (MTD):

  • MLN0128 QD
  • MLN0128 QW
  • MLN0128 QDx3dQW
  • MLN0128 QDx5dQW

MLN0128 capsule, orally, once daily (QD) or Once weekly (QW) in the Dose Escalation Phase until MTD was established.

Once MTD was determined, participants were then enrolled in the Dose Expansion Phase to receive:

  • MLN0128 5 mg QD
  • MLN0128 30 mg QW
  • MLN0128 40 mg QW

This multi-centre trial was conducted worldwide. The overall time to participate in this study was approximately 244 weeks. Participants will make multiple visits to the clinic, and were contacted by telephone OR plus a final visit after last dose of study drug for a follow-up assessment.

研究类型

介入性

注册 (实际的)

198

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Scottsdale、Arizona、美国
    • California
      • Los Angeles、California、美国
    • Florida
      • Miami、Florida、美国
      • Sarasota、Florida、美国
    • Indiana
      • Indianapolis、Indiana、美国
    • Massachusetts
      • Boston、Massachusetts、美国
    • Michigan
      • Ann Arbor、Michigan、美国
      • Detroit、Michigan、美国
    • New York
      • Buffalo、New York、美国
      • New York、New York、美国
    • Ohio
      • Cleveland、Ohio、美国
    • Oklahoma
      • Oklahoma City、Oklahoma、美国
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国
    • Tennessee
      • Nashville、Tennessee、美国
      • Barcelona、西班牙
      • Valencia、西班牙

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Voluntary written consent
  • Locally advanced or metastatic solid tumors with the exception of primary brain tumor, and have failed standard of care therapy
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Ability to swallow oral medications
  • For women of child-bearing potential, negative serum or urine pregnancy test within 14 days prior to the first study drug administration and use of physician-approved method of birth control from 30 days prior to 90 days following the last study drug administration
  • Male participants must be surgically sterile or must agree to use physician-approved contraception during the study and for 90 days following the last study drug administration
  • Clinical laboratory values as specified in the protocol

Additionally, to be eligible for the Dose Expansion portion of the study:

  • Participants must have evidence of measurable disease per response evaluation criteria in solid tumors (RECIST) version 1.1 by radiographic techniques or magnetic resonance imaging
  • Participants must have a pathologic diagnosis of advanced or recurrent endometrial adenocarcinoma and must have failed at least 1 prior line of standard chemotherapy
  • Participants must have a pathologic diagnosis of advanced/metastatic urothelial cancer (carcinoma of the bladder, ureter, and/or renal pelvis) and must have failed at least 1 line of prior therapy in the metastatic/unresectable setting
  • Participants must have a pathologic diagnosis of advanced renal cell carcinoma (RCC), with histological or cytological confirmation of RCC and must have failed at least 1 prior line of anti-vascular endothelial growth factor therapy (VEGF) therapy (including but not limited to sunitinib, and/or sorafenib, and/or bevacizumab and/or pazopanib, and/or axitinib) and must not have received prior therapy with a target of rapamycin complex 1 (TORC1) inhibitor (such as temsirolimus or everolimus); or
  • Participants must have a pathologic diagnosis of advanced renal cell carcinoma (RCC) and must have progressed on treatment with a TORC1 inhibitor (such as temsirolimus or everolimus).

Exclusion Criteria:

  • Diagnosis of primary brain tumor
  • Have received prior cancer or other investigational therapy within 2 weeks prior to the first administration of study drug
  • Known impaired cardiac function or clinically significant cardiac disease
  • Known treatment with systemic corticosteroid within one week prior to the first administration of study drug
  • Diabetes mellitus
  • Human immunodeficiency virus (HIV) infection
  • Known active cardiovascular disease condition as specified in protocol
  • Failed to recover from the reversible effects of prior anticancer therapies
  • Pregnancy (positive serum or urine pregnancy test) or breast feeding
  • Malabsorption due to prior gastrointestinal (GI) surgery, GI disease
  • Other clinically significant co-morbidities

Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.

Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:MLN0128 QD
MLN0128 2 mg, 4 mg, 6 mg or 7 mg, capsule, orally, once daily (QD) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 52.1 weeks).
MLN0128 capsules
其他名称:
  • INK128
  • TAK-128
实验性的:MLN0128 QW
MLN0128 7 mg, 10 mg, 15 mg, 20 mg, 30 mg or 40 mg capsule, orally, once weekly (QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 139.4 weeks).
MLN0128 capsules
其他名称:
  • INK128
  • TAK-128
实验性的:MLN0128 QDx3d QW
MLN0128 6 mg, 9 mg, 12 mg, 16 mg or 20 mg capsule, orally, once daily every 3 days a week (QDx3d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 129.4 weeks).
MLN0128 capsules
其他名称:
  • INK128
  • TAK-128
实验性的:MLN0128 QDx5d QW
MLN0128 7 mg, 10 mg or 13 mg capsule, orally, once daily every 5 days a week (QDx5d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 161.9 weeks).
MLN0128 capsules
其他名称:
  • INK128
  • TAK-128
实验性的:MLN0128 5 mg QD
MLN0128 5 mg, capsule, orally, QD in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 98.3 weeks).
MLN0128 capsules
其他名称:
  • INK128
  • TAK-128
实验性的:MLN0128 30 mg QW
MLN0128 30 mg, capsule, orally QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 240 weeks).
MLN0128 capsules
其他名称:
  • INK128
  • TAK-128
实验性的:MLN0128 40 mg QW
MLN0128 40 mg, capsule, orally, QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 100.1 weeks).
MLN0128 capsules
其他名称:
  • INK128
  • TAK-128

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Dose Escalation Phase: Maximum Tolerated Dose (MTD)
大体时间:Cycle 1 (28 Days)
MTD was defined as the highest dose level of MLN0128 at which no more than 1 out of 6 evaluable participants experienced a DLT during the first cycle (28 days) of therapy.
Cycle 1 (28 Days)
Dose Escalation Phase: Number of Participants With Dose Limiting Toxicities (DLTs)
大体时间:Cycle 1 (28 days)
DLTs were defined as MLN0128-related treatment-emergent adverse events (TEAEs) that occurred within the Cycle 1 (first 28 days of treatment) as per Common Terminology Criteria for Adverse Events (CTCAE): Any ≥Grade 3 or non-hematologic toxicity except for Grade 3 nausea and/or vomiting and diarrhea, Grade 3 hyperglycemia lasting ≤ 14 days, Grade 3 rash lasting ≤ 3 days; Grade 4 neutropenia lasting >7 days in the absence of growth factor support; Grade 4 neutropenia of any duration associated with fever ≥38.5 degree celsius and/or systemic infection; Any other Grade 4 hematologic toxicity; Inability to administer at least 75% of planned doses of MLN0128 within Cycle 1 due to drug-related toxicity and any clinically significant occurrence that the investigators and sponsor agreed would place participants at an undue safety risk.
Cycle 1 (28 days)
Number of Participants Experiencing One or More Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Resulting in Discontinuation of MLN0128 and Fatal AEs Within 30 Days of Last Dose of Study Drug
大体时间:First dose of study drug through 30 days after the administration of the last dose of study drug (Up to approximately 244 weeks)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
First dose of study drug through 30 days after the administration of the last dose of study drug (Up to approximately 244 weeks)
Dose Expansion: Objective Response Rate (ORR)
大体时间:From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
ORR is defined as the percentage of participants who achieved complete response (CR) or partial response (PR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. CR is defined as disappearance of all target lesions and PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions. Data was categorized as per type of cancer.
From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
Dose Expansion Phase: Duration of Objective Response
大体时间:From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
Duration of objective response is defined as the number of months from the start date of CR or PR (whichever occurred first) based on RECIST Criteria version 1.1 to the first date of objectively documented progressive disease (PD) for participants who achieved CR or PR. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
Dose Expansion: Duration of Stable Disease (SD)
大体时间:From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
Duration of SD was evaluated for participants with best response of SD and is defined as number of months from date of first dose to date of PD. As per RECIST 1.1, SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PR was defined of at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions. PD is defined as at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (this includes baseline sum if that is smallest on study).
From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)

次要结果测量

结果测量
措施说明
大体时间
Cmax: Maximum Observed Plasma Concentration for MLN0128
大体时间:Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Ctrough: Observed Concentration at the End of a Dosing Interval
大体时间:Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Terminal Phase Elimination Half-life (T1/2) for MLN0128
大体时间:Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN0128
大体时间:Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MLN0128
大体时间:Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Tmax: Time to Maximum Observed Plasma Concentration for MLN0128
大体时间:Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Percentage Area Under Plasma Concentration Time Curve Extrapolated
大体时间:Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Percentage Change From Baseline in Eukaryotic Initiation Factor 4E-binding Protein 1 (P4EBP1), Serine/Threonine Protein Kinase B (PAKT) and Ribosomal Protein S6 (PS6)
大体时间:Baseline, Cycle 1 Week 2
P4EBP, PAKT and PS6 were assayed in skin biopsies. A negative percentage change from Baseline indicates improvement.
Baseline, Cycle 1 Week 2

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2010年1月4日

初级完成 (实际的)

2019年2月7日

研究完成 (实际的)

2019年2月7日

研究注册日期

首次提交

2010年1月27日

首先提交符合 QC 标准的

2010年1月27日

首次发布 (估计)

2010年1月29日

研究记录更新

最后更新发布 (实际的)

2020年4月1日

上次提交的符合 QC 标准的更新

2020年3月18日

最后验证

2020年3月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • INK128-001
  • 2009-017284-42 (EudraCT编号)
  • U1111-1187-4258 (其他标识符:World Health Organization)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅